• Innovent Biologics targets total revenue of RMB 35 billion to RMB 40 billion by 2030, with profit margins benchmarked against top-tier pharmaceutical companies.
• Strategic goals include advancing at least five molecules into global multi-regional Phase 3 development by 2030, with launches in key US and European markets.
• Third-quarter 2026 product revenue exceeded RMB 4.7 billion, up over 40% year over year, supported by general biomedicine expansion and oncology sales growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261029-12386909), on October 28, 2026, and is solely responsible for the information contained therein.